יחס חוב לטווח קצר להון עצמי: Pasithea Therapeutics Corp. (KTTA)

The current market value of Pasithea Therapeutics (KTTA) shown on this chart reflects the dynamics of a company whose research depends on the stable import of rare reagents and international cooperation. Human capital is secured by the loyalty of leading neurobiologists, which eliminates the risk of losing expertise. The indicator stands at 0.00. The business focuses on the therapy of mental disorders; therefore, project success is determined by clinical achievements rather than market cycles.

To assess the credit quality of Pasithea Therapeutics (KTTA), the analyst utilizes the short-term debt-to-equity ratio, which compares liabilities maturing within one year against the company's own funds to identify liquidity risks associated with financing the development of the PAS-004 drug and AI projects, where a low level of this metric confirms the biotech startup's financial stability ahead of potential M&A transactions.